Premium
Antihypertensive efficacy and tolerability of enalapril and slow‐release verapamil in essential hypertension: a double‐blind, cross‐over study
Author(s) -
FAGHER B.,
KATZMAN P.,
HULTHÉN U. L.,
HENNINGSEN N. C.,
THULIN T.
Publication year - 1991
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1991.tb00434.x
Subject(s) - medicine , tolerability , enalapril , verapamil , essential hypertension , supine position , placebo , blood pressure , double blind , diastole , anesthesia , angiotensin converting enzyme , adverse effect , calcium , alternative medicine , pathology
. The antihypertensive efficacy and tolerability of enalapril (E) and slow‐release verapamil (V) were compared in a 2‐month double‐blind cross‐over study in 22 patients with mild to moderate essential hypertension. After 1 month, significantly lower systolic (P < 0.01) and diastolic (P < 0.02) blood pressures (BP) were achieved with E, 20 mg d −1 , compared with V, 240 mg d −1 . After 2 months of treatment, BP reductions were similar after E, 40 mg d −1 , and V, 240 mg twice a day. The fall in supine mean BP after 2 months of treatment with V was significantly greater in patients aged ≥ 50 years of age (P = 0.02) (median 18 mmHg) than in patients aged < 50 years (10 mmHg). E showed similar effectiveness in both age groups. Statistical group analysis of a quality‐of‐life questionnaire showed no significant differences between the active drugs and the placebo. It is concluded that E and V are equally effective as antihypertensive agents, and that both drugs are well tolerated.